Homepage4142 • TPE
add
Adimmune Corp
Vorige slotkoers
NT$ 18,95
Dag-range
NT$ 18,80 - NT$ 19,10
Jaar-range
NT$ 15,90 - NT$ 27,00
Beurswaarde
8,14 mld. TWD
Gem. volume
1,67 mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
TPE
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (TWD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 475,32 mln. | -46,49% |
Bedrijfskosten | 146,27 mln. | -14,74% |
Netto inkomsten | -18,26 mln. | -106,93% |
Netto winstmarge | -3,84 | -112,96% |
Winst per aandeel | — | — |
EBITDA | -19,68 mln. | -106,24% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (TWD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 1,79 mld. | -3,29% |
Totale activa | 8,38 mld. | -2,80% |
Totale passiva | 3,53 mld. | 18,40% |
Totaal aandelenvermogen | 4,85 mld. | — |
Uitstaande aandelen | 421,51 mln. | — |
Koers-boekwaardeverhouding | 1,69 | — |
Rendement op activa | -1,86% | — |
Rendement op kapitaal | -1,94% | — |
Kasstroom
Nettomutatie in liquide middelen
| (TWD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -18,26 mln. | -106,93% |
Operationele kasstroom | -355,08 mln. | -17,80% |
Kasstroom uit beleggingen | -173,61 mln. | -102,13% |
Kasstroom uit financiering | 403,21 mln. | 5.593,35% |
Nettomutatie in liquide middelen | -117,89 mln. | 70,35% |
Vrije kasstroom | -460,83 mln. | -29,17% |
Over
Adimmune Corporation is a Taiwanese biopharmaceutical company headquartered in Taichung. Originally founded in 1965 as Taiwan’s first vaccine laboratory, it later evolved into a modern vaccine manufacturer and contract development and manufacturing organization. The company is notable for being the only influenza vaccine manufacturer in Asia certified by both the European Union Good Manufacturing Practice and the U.S. Food and Drug Administration, and the*only human vaccine manufacturer in Taiwan operating under PIC/S GMP standards. Wikipedia
Opgericht
1965
Website
Werknemers
564
